Pipelines

Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND
MDSC Target 1
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

32%
MDSC Target 2
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

32%
T-cell Target 1
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

25%
Ocular Melanoma
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

15%

Immuno-oncology

  IMM-IO-100

Immuneering is developing IMM-IO-100 as an agent that targets an immune regulatory receptor located on the surface of tolerizing M2 macrophages and myeloid-derived suppressor cells (MDSC). Inhibition of the receptor results in myeloid cell differentiation and helps promote activation and effector functions in T lymphocytes restoring anti-tumor immunity.

  IMM-IO-101

Immuneering is developing IMM-IO-101 as an agent that targets another immune regulatory receptor located on the surface of tolerizing M2 macrophages and myeloid-derived suppressor cells (MDSC), and on immature neutrophils. Inhibition of the receptor results in myeloid and neutrophil cell differentiation and helps promote activation and effector functions in T lymphocytes restoring anti-tumor immunity.

  IMM-IO-200

Immuneering is developing IMM-IO-200 as an accessory T cell checkpoint that blocks activation and function of tumor-reactive T cells. Inhibition of this checkpoint helps promote T cell activation and is being evaluated alone and in combination with related immune checkpoint inhibitors as a strategy to restore effective tumor immunotherapy.

  IMM-IO-300

Immuneering is developing IMM-IO-300 for uveal (ocular) melanoma. IMM-IO-300 is a novel small molecule inhibitor being developed to inhibit one of the most highly expressed genes in poor risk uveal melanoma cells. Targeting this gene utilizes Immuneering’s disease cancelling technology to restore normal gene function to reverse the neoplastic phenotype in ocular melanoma cells.